Cytori Therapeutics, Inc
Cytori Chairman Marshall G. Cox Retires; Ronald D. Henriksen Appointed as Interim Chairman

 
Cytori Therapeutics, Inc. / Change of Personnel 
 
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by 
DGAP – a company of EquityStory AG. 
The issuer is solely responsible for the content of this announcement. 
———————————————————————- 
 
Cytori Therapeutics, Inc. (NASDAQ: CYTX; Frankfurt: XMPA) announces the 
retirement of Marshall G. Cox from the board of directors, effective May 3, 
2007. Mr. Cox, who will be providing consulting services to Cytori, is 
being honored with recognition as Chairman Emeritus for his founding 
efforts and ten years of dedicated service as Cytori’s Chairman of the 
Board. Independent director Ronald D. Henriksen was appointed by the board 
to serve as Interim Chairman. 
 
————————————————————————— 
 
Information and Explaination of the Issuer to this News: 
 
‘I am grateful to have had the opportunity to work with such a talented 
team of directors, scientists, and engineers at Cytori who have quickly and 
effectively built a company that is at the forefront of regenerative 
medicine,’ said Mr. Cox. ‘Cytori’s strong management will help the Company 
continue its growth as Cytori expands its exciting development pipeline and 
prepares to launch the Celution™ regenerative cell processing system.’ 
 
‘I am personally grateful to Mr. Cox for his mentorship, strategic 
guidance, founding investment and innumerable contributions that were 
instrumental to our development and success in regenerative medicine,’ said 
Christopher J. Calhoun, Chief Executive Officer for Cytori. ‘We look 
forward to the board maintaining its strong leadership under Mr. Henriksen, 
who will continue to contribute valuable experience gained from his time at 
leading biotechnology, pharmaceutical, and medical device companies.’ 
 
Mr. Henriksen joined Cytori as Director in 2002. He brings to Cytori over 
30 years of healthcare, pharmaceutical, biotechnology, consulting and 
venture experience. He is currently the Chief Investment Officer of 
Twilight Ventures Partners, LLC, Chairman of the Board of Semafore 
Pharmaceuticals, Chief Executive Officer of EndGenitor Technologies, and a 
director for QLT, Inc., Canada’s largest biopharmaceutical 
company. 
 
 
 
 
DGAP 04.05.2007  
———————————————————————- 
  
Language:     English 
Issuer:       Cytori Therapeutics, Inc. 
              6740 Top Gun Street 
              92121 San Diego, CA Vereinigte Staaten von Amerika 
Phone:        001-858 / 736 5485 
Fax:          001-858 / 458 0994 
E-mail:       sbacher@cytoritx.com 
www:          www.cytoritx.com 
ISIN:         US23283K1051 
WKN:          A0ETV6 
Indices:      PRIMEALL, TECHALLSHARE 
Listed:       Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr 
              in Berlin-Bremen, Stuttgart, München, Düsseldorf 
  
End of News                                     DGAP News-Service 
  
—————————————————————————